MeiraGTx Holdings plc Deferred Income Tax Expense (Benefit)
MeiraGTx Holdings plc (MGTX) reported Deferred Income Tax Expense (Benefit) of -$21.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-30
- MeiraGTx Holdings plc deferred income tax expense (benefit) for fiscal 2025 was -$21.29M.
- MeiraGTx Holdings plc deferred income tax expense (benefit) for fiscal 2024 was -$24.04M.
- MeiraGTx Holdings plc deferred income tax expense (benefit) for fiscal 2023 was -$9.66M.
- MeiraGTx Holdings plc deferred income tax expense (benefit) for fiscal 2022 was -$25.95M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$21.29M 10-K · filed 2026-03-30 | |
| 2024-12-31 | -$24.04M 10-K · filed 2026-03-30 | |
| 2023-12-31 | -$9.66M 10-K · filed 2025-03-13 | |
| 2022-12-31 | -$25.95M 10-K · filed 2024-03-15 | |
| 2021-12-31 | -$36.96M 10-K · filed 2023-03-14 | |
| 2020-12-31 | -$15.79M 10-K · filed 2022-03-10 | -$15.79M 10-K · filed 2021-03-11 |
| 2019-12-31 | -$9.75M 10-K · filed 2021-03-11 | -$9.75M 10-K · filed 2020-03-11 |
| 2018-12-31 | -$12.49M 10-K · filed 2020-03-11 | |
| 2017-12-31 | -$4.94M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |